Preservation of Endopelvic Fascia During Radical Prostatectomy: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostatic Neoplasms
- Sponsor
- Tampere University Hospital
- Enrollment
- 158
- Locations
- 1
- Primary Endpoint
- Erectile function
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Urinary incontinence and impotence are typical disturbances after radical prostatectomy. Although, several surgical methods are developed to decrease these disturbances, 8% and 50% of the patients suffer from permanent urinary incontinence and impotence, respectively.
Previously two studies have shown that endopelvic fascia preservation may decrease postoperative incontinence and impotence rates. Unfortunately these studies are retrospective decreasing their reliability.
The present study is prospective and randomized clinical trial. The investigators are going to randomize 180 patient to preservation and opening the endopelvic fascia groups. Functional and oncological results are followed up to 1 year after surgery.
Detailed Description
180 patients going to radical prostatectomy as treatment of prostate cancer will be randomized 1:1 to two study arms: In the other arm endopelvic fascia are preserved during the operation, in the other arm the fascia are opened. After the operation urinary continence and erection function are compared between the study arms. Additionally the investigators will study oncological outcomes.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Localized prostate cancer
- •Planned nerve-sparing robotic radical prostatectomy
- •Gleason score 7 or less
Exclusion Criteria
- •Previous prostate surgery (TURP, TUIP, laser...)
- •Planned lymphadenectomy
- •T3 cancer
Outcomes
Primary Outcomes
Erectile function
Time Frame: 1 year
EPIC-26 questionnaire preoperatively and 3 and 12 months after surgery
Urinary incontinence
Time Frame: 1 year
EPIC-26 questionnaire preoperatively and 3 and 12 months after surgery
Secondary Outcomes
- Complications(1 year)
- Oncologic results: positive surgical margin rate(1 year)